[go: up one dir, main page]

MX2018005461A - Metodos para tratar cancer usando compuestos de pirimidina y piridina con actividad inhibidora de tirosina cinasa de bruton. - Google Patents

Metodos para tratar cancer usando compuestos de pirimidina y piridina con actividad inhibidora de tirosina cinasa de bruton.

Info

Publication number
MX2018005461A
MX2018005461A MX2018005461A MX2018005461A MX2018005461A MX 2018005461 A MX2018005461 A MX 2018005461A MX 2018005461 A MX2018005461 A MX 2018005461A MX 2018005461 A MX2018005461 A MX 2018005461A MX 2018005461 A MX2018005461 A MX 2018005461A
Authority
MX
Mexico
Prior art keywords
pyrimidine
methods
pyridine compounds
inhibitory activity
treating cancer
Prior art date
Application number
MX2018005461A
Other languages
English (en)
Other versions
MX388890B (es
Inventor
R Huck Bayard
M Goodstal Samantha
Gimmi-Mckim Claude
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of MX2018005461A publication Critical patent/MX2018005461A/es
Publication of MX388890B publication Critical patent/MX388890B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona métodos para el tratamiento del cáncer usando compuestos de pirimidina y piridina que son inhibidores de tirosina cinasa de Bruton (BTK, por sus siglas en inglés).
MX2018005461A 2015-11-04 2016-11-04 Metodos para tratar cancer usando compuestos de pirimidina y piridina con actividad inhibidora de tirosina cinasa de bruton. MX388890B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562250575P 2015-11-04 2015-11-04
US201662296143P 2016-02-17 2016-02-17
US201662341189P 2016-05-25 2016-05-25
PCT/US2016/060508 WO2017079542A1 (en) 2015-11-04 2016-11-04 Methods for treating cancer using pyrimidine and pyridine compounds with btk inhibitory activity

Publications (2)

Publication Number Publication Date
MX2018005461A true MX2018005461A (es) 2018-08-01
MX388890B MX388890B (es) 2025-03-20

Family

ID=57442803

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018005461A MX388890B (es) 2015-11-04 2016-11-04 Metodos para tratar cancer usando compuestos de pirimidina y piridina con actividad inhibidora de tirosina cinasa de bruton.
MX2021015826A MX2021015826A (es) 2015-11-04 2018-04-30 Metodos para tratar cancer usando compuestos de pirimidina y piridina con actividad inhibidora de tirosina cinasa de bruton.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021015826A MX2021015826A (es) 2015-11-04 2018-04-30 Metodos para tratar cancer usando compuestos de pirimidina y piridina con actividad inhibidora de tirosina cinasa de bruton.

Country Status (23)

Country Link
US (4) US20170119766A1 (es)
EP (2) EP4014977A1 (es)
JP (4) JP6913100B2 (es)
KR (2) KR20250133463A (es)
CN (1) CN108779095B (es)
AU (4) AU2016349584B9 (es)
BR (1) BR112018007604B1 (es)
CA (1) CA3001735A1 (es)
CY (1) CY1125116T1 (es)
DK (1) DK3371165T3 (es)
ES (1) ES2912059T3 (es)
HU (1) HUE058323T2 (es)
IL (2) IL293093B2 (es)
LT (1) LT3371165T (es)
MX (2) MX388890B (es)
NZ (1) NZ741293A (es)
PL (1) PL3371165T3 (es)
RS (1) RS63146B1 (es)
RU (2) RU2022100782A (es)
SG (2) SG11201802927VA (es)
SI (1) SI3371165T1 (es)
TW (3) TWI783915B (es)
WO (1) WO2017079542A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2022100782A (ru) * 2015-11-04 2022-02-03 Мерк Патент Гмбх Способы лечения злокачественной опухоли с использованием соединений пиримидина и пиридина с btk ингибирующей активностью
ES2964946T3 (es) * 2015-11-17 2024-04-10 Merck Patent Gmbh Métodos para tratar esclerosis múltiple usando compuestos de pirimidina con actividad inhibidora de tirosina cinasa de bruton
EP3618818A4 (en) * 2017-05-03 2020-12-09 Vivace Therapeutics, Inc. NON-CONDENSED TRICYCLIC COMPOUNDS
MY206797A (en) * 2018-06-19 2025-01-08 Merck Patent Gmbh Novel crystalline forms of 1-(4-{[6-amino-5-(4-phenoxy-phenyl)-pyrimidin-4-ylamino]-methyl}-4-fluoro-piperidin-1-yl)-propenone, salt forms thereof, and processes to obtain
CA3103943A1 (en) 2018-07-25 2020-01-30 Novartis Ag Nlrp3 inflammasome inhibitors
AR119731A1 (es) 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
US20240024314A1 (en) * 2020-01-08 2024-01-25 Telios Pharma, Inc. Methods of Treating Splenomegaly
AU2021325431B2 (en) 2020-08-14 2024-01-18 Novartis Ag Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof
CN112250666B (zh) * 2020-10-09 2022-01-14 广东东阳光药业有限公司 取代的嘧啶类化合物及其用途
EP4255569A4 (en) * 2020-12-02 2024-10-23 Telios Pharma, Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF AN OPHTHALMIC CONDITION
WO2022206939A1 (zh) * 2021-04-03 2022-10-06 海南耀臻生物医药科技有限公司 作为fgfr抑制剂的杂环化合物及其应用
US11866421B2 (en) 2021-05-31 2024-01-09 Epigen Biosciences, Inc. Pyrimidine and pyridine amine compounds and usage thereof in disease treatment
WO2023137182A1 (en) * 2022-01-14 2023-07-20 Telios Pharma Inc. Methods of treating myeloproliferative disorders based on btk occupancy & resynthesis rate
US20260000669A1 (en) 2022-06-24 2026-01-01 Merck Patent Gmbh Treatment regimen for autoimmune diseases and inflammatory diseases
UY40374A (es) 2022-08-03 2024-02-15 Novartis Ag Inhibidores de inflamasoma nlrp3

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19649896A1 (de) * 1996-12-02 1998-06-04 Henkel Kgaa Geformte Seifenprodukte
JP2002514195A (ja) * 1996-12-05 2002-05-14 アムジエン・インコーポレーテツド 置換ピリミジン化合物およびそれの使用
KR101216372B1 (ko) * 2004-03-30 2013-01-04 버텍스 파마슈티칼스 인코포레이티드 Ｊａｋ 및 기타 단백질 키나제의 억제제로서 유용한 아자인돌
EP2211615A4 (en) * 2007-10-22 2010-10-13 Glaxosmithkline Llc PYRIDOSULFONAMIDE DERIVATIVES AS PI3 KINASE INHIBITORS
CL2009001152A1 (es) 2008-05-13 2009-10-16 Array Biopharma Inc Compuestos derivados de n-(4-(cicloalquilo nitrogenado-1-il)-1h-pirrolo[2,3-b]piridin-3-il)amida, inhibidores de cinasa; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa.
KR20140007954A (ko) * 2011-06-10 2014-01-20 메르크 파텐트 게엠베하 Btk 억제 활성을 갖는 피리미딘 및 피리딘 화합물의 조성물 및 제조방법
TW201414734A (zh) * 2012-07-10 2014-04-16 Takeda Pharmaceutical 氮雜吲哚衍生物
WO2014093230A2 (en) * 2012-12-10 2014-06-19 Merck Patent Gmbh Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity
US8895750B2 (en) * 2013-03-14 2014-11-25 Boehringer Ingelheim International Gmbh Heteroaromatic compounds as BTK inhibitors
AU2014321420B2 (en) * 2013-09-22 2017-06-15 Sunshine Lake Pharma Co., Ltd. Substituted aminopyrimidine compounds and methods of use
GB201404987D0 (en) 2014-03-20 2014-05-07 Redx Pharma Ltd Compounds
RU2022100782A (ru) * 2015-11-04 2022-02-03 Мерк Патент Гмбх Способы лечения злокачественной опухоли с использованием соединений пиримидина и пиридина с btk ингибирующей активностью
ES2964946T3 (es) * 2015-11-17 2024-04-10 Merck Patent Gmbh Métodos para tratar esclerosis múltiple usando compuestos de pirimidina con actividad inhibidora de tirosina cinasa de bruton

Also Published As

Publication number Publication date
SI3371165T1 (sl) 2022-05-31
JP7295169B2 (ja) 2023-06-20
JP2025023232A (ja) 2025-02-14
US20250161304A1 (en) 2025-05-22
AU2016349584B9 (en) 2021-06-03
MX388890B (es) 2025-03-20
JP2018532805A (ja) 2018-11-08
IL293093A (en) 2022-07-01
JP2021165308A (ja) 2021-10-14
US20200206224A1 (en) 2020-07-02
EP3371165A1 (en) 2018-09-12
ES2912059T3 (es) 2022-05-24
AU2016349584B2 (en) 2021-05-13
RU2018120153A3 (es) 2020-03-05
TW202320784A (zh) 2023-06-01
RS63146B1 (sr) 2022-05-31
BR112018007604A2 (pt) 2018-10-23
SG10202005292UA (en) 2020-07-29
TW201722430A (zh) 2017-07-01
EP4014977A1 (en) 2022-06-22
KR20250133463A (ko) 2025-09-05
US20170119766A1 (en) 2017-05-04
TW202510883A (zh) 2025-03-16
IL258979A (en) 2018-06-28
DK3371165T3 (da) 2022-05-02
AU2021211982A1 (en) 2021-08-26
RU2018120153A (ru) 2019-12-05
RU2765154C2 (ru) 2022-01-26
US20210244736A1 (en) 2021-08-12
TWI858413B (zh) 2024-10-11
IL293093B1 (en) 2024-03-01
RU2022100782A (ru) 2022-02-03
KR102850604B1 (ko) 2025-08-27
LT3371165T (lt) 2022-05-10
CA3001735A1 (en) 2017-05-11
WO2017079542A1 (en) 2017-05-11
US11491153B2 (en) 2022-11-08
CN108779095B (zh) 2025-12-23
CN108779095A (zh) 2018-11-09
AU2021211982B2 (en) 2023-03-02
JP6913100B2 (ja) 2021-08-04
SG11201802927VA (en) 2018-05-30
AU2016349584A1 (en) 2018-04-26
IL258979B (en) 2022-06-01
PL3371165T3 (pl) 2022-05-02
AU2023203377A1 (en) 2023-06-29
TWI783915B (zh) 2022-11-21
NZ741293A (en) 2023-06-30
KR20180073599A (ko) 2018-07-02
IL293093B2 (en) 2024-07-01
MX2021015826A (es) 2022-02-03
BR112018007604B1 (pt) 2022-08-16
EP3371165B1 (en) 2022-01-26
AU2025204315A1 (en) 2025-06-26
HUE058323T2 (hu) 2022-07-28
JP2023105214A (ja) 2023-07-28
CY1125116T1 (el) 2024-12-13

Similar Documents

Publication Publication Date Title
MX2018005461A (es) Metodos para tratar cancer usando compuestos de pirimidina y piridina con actividad inhibidora de tirosina cinasa de bruton.
MX2018005463A (es) Metodos para tratar esclerosis multiple usando compuestos de pirimidina y piridina con actividad inhibidora de tirosina cinasa de bruton.
CO2019008783A2 (es) Compuestos dinucleotidos ciclicos para el tratamiento del cancer
CO2017012947A2 (es) Inhibidores de tirosina-cinasas
CL2018001152A1 (es) Composiciones y métodos para el tratamiento del cáncer
CL2019002427A1 (es) Inhibición de smarca2 para el tratamiento de cáncer.
CL2018003123A1 (es) Terapia de combinación para el tratamiento del cáncer
EA201692511A1 (ru) Комбинированное лечение ингибиторами глутаминазы
ECSP17073743A (es) Moduladores de k-ras
BR112019002331A2 (pt) anticorpos anti-siglec-7 para o tratamento do câncer e métodos para obtenção dos mesmos
MX2020000386A (es) Inhibidores heterociclicos de la cinasa atr.
PL3580211T3 (pl) 2-heteroarylo-3-okso-2,3-dihydropirydazyno-4-karboksyamidy do leczenia nowotworu
MX2016002137A (es) Ciertas entidades quimicas, composiciones y metodos.
BR112018001853A2 (pt) métodos para tratamento de um distúrbio e para melhoria do tratamento de um distúrbio
MX373341B (es) INHIBIDORES DE PROTEíNA CINASA 2 ACTIVADA POR PROTEíNA CINASA ACTIVADA POR MITóGENO (MK2) Y SUS USOS.
MX2018003301A (es) Inhibidores de pcna.
MX382904B (es) Combinaciones de fármacos para tratar mieloma múltiple.
PH12017501879A1 (en) Methods for treating cancer
TW201613587A (en) Medical treatments based on anamorelin
LT3534885T (lt) Farneziltransferazės inhibitoriai, skirti naudoti vėžio gydymui
CL2017000006A1 (es) Derivados de quinolizinona como inhibidores de pi3k
MX2018014938A (es) Combinaciones farmaceuticas para el tratamiento del cancer.
MX2016009655A (es) Metodos novedosos para el tratamiento del cancer.
CY1125266T1 (el) To rad1901 για χρηση στη θεραπεια του καρκινου των ωοθηκων
DOP2017000136A (es) Compuestos para tratar el cáncer